SynthesisBMC nephrology2025
Parathyroidectomy in the treatment of uremic tumoral calcinosis: a 9-year case report and meta-analysis.
Synthesis in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveUremic tumoral calcinosis (UTC) is a relatively rare but challenging complication in dialysis patients, characterized by abnormal calcium salt deposition. Parathyroidectomy (PTX) is a commonly used treatment; however, some patients experience limited postoperative symptom improvement, suggesting potential factors that affect PTX efficacy. This study aims to investigate the mechanisms underlying suboptimal remission of UTC after PTX to optimize treatment strategies and improve patient outcomes.
methodsWe report a case of a maintenance hemodialysis patient whose UTC worsened after PTX. Following discontinuation of active vitamin D and intensified phosphorus management, the patient's calcium-phosphorus product significantly decreased, accompanied by marked regression of calcified lesions. To further explore possible mechanisms, we reviewed and analyzed previous literature on PTX treatment for UTC and compared our case with related reports.
resultsOur findings demonstrate considerable individual variability in PTX efficacy for UTC treatment, with calcium-phosphorus product (Ca×P) levels playing a critical role in patient prognosis. This study suggests that calcium-phosphorus metabolism may be a key factor influencing PTX outcomes.
conclusionsThis case highlights the importance of controlling the calcium-phosphorus product in treating UTC.Postoperative management should focus on optimizing calcium-phosphorus metabolism, with particular attention to individualized phosphorus control strategies and appropriate use of active vitamin D.These approaches are crucial for enhancing PTX efficacy and improving long-term patient prognosis. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.